Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17793354 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6NLRP3 | |
| SCHEMBL14865081 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6NLRP3 | |
| SCHEMBL18193512 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6NLRP3 | |
| SCHEMBL9269248 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6NLRP3 | |
| SCHEMBL611777 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6NLRP3 | |
| SCHEMBL2624020 | 0.97 | — | — | |
| SCHEMBL477153 | 0.92 | — | — | |
| SCHEMBL15045493 | 0.91 | CES2 (0.42) | CES2CES1HDAC8HDAC6NLRP3 | |
| SCHEMBL18374076 | 0.91 | CES2 (0.42) | CES2CES1HDAC8HDAC6NLRP3 | |
| SCHEMBL18373930 | 0.89 | CES2 (0.41) | CES2CES1HDAC8HDAC6NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020223538-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| EP-1912986-B1 | IMIDIAZO -AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8158648-B2 | Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors | LI JAMES J (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158648-B2 | Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors | LI JAMES J (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158648-B2 | Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors | LI JAMES J (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090306084-A1 | HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090306084-A1 | HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090306084-A1 | HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-7572807-B2 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572807-B2 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572807-B2 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1912986-A1 | IMIDIAZO -AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I | Brystol-Myers Squibb Company (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006135667-A1 | IMIDIAZO -AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281750-A1 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-14 | — | — | US | disclosed |
| EP-0885869-A1 | THERAPEUTIC AGENT FOR DIABETES | Japan Tobacco Inc. (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5399702-A | Leukotriene antagonists; antiasthmatic, antiallergen, and antianaphylactic agents | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0577003-A1 | Thiazolylvinylphenyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1994-01-05 | — | — | EP | disclosed |
| US-5273986-A | A substituted phenylalkyleneamidophenyleneethylene thiazole | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306084-A1 | HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD17B1, HSD11B2 | CES2 420/4885CES1 20/4885HDAC8 969/4885 |
| US-20060281750-A1 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors | HSD11B1, HSD17B1, HSD11B2 | CES2 418/4885CES1 22/4885HDAC8 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.